NBIX – neurocrine biosciences, inc. (US:NASDAQ)
Stock Stats
News
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR [Yahoo! Finance]
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $179.00 to $177.00. They now have an "overweight" rating on the stock.
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Truist Financial Corporation from $172.00 to $169.00. They now have a "buy" rating on the stock.
Neurocrine Biosciences (NASDAQ:NBIX) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $175.00 price target on the stock, up previously from $173.00.
Form 4 NEUROCRINE BIOSCIENCES For: Jan 08 Filed by: Lippoldt Darin
Form 4 NEUROCRINE BIOSCIENCES For: Dec 15 Filed by: Norwalk Leslie V
Form 144 NEUROCRINE BIOSCIENCES Filed by: Norwalk Leslie V
Form 4 NEUROCRINE BIOSCIENCES For: Dec 08 Filed by: Lippoldt Darin
Form 144 NEUROCRINE BIOSCIENCES Filed by: Lippoldt Darin
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.